Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
AssigneeALSaTECH, Inc.
InventorsClaude Nicolau, Claudine Kieda, Reynald Thinard, Ruth Greferath, Melanie Chevalier
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.
Claims9
A method for solubilizing TDP-43 protein aggregates in a subject having Amyotrophic Lateral Sclerosis (ALS), comprising administering to the subject a microvascular endothelial cell (MEC) comprising a nucleic acid encoding an anti-TDP-43 Fab, wherein the MEC traffics and releases the anti-TDP-43 Fab past the blood brain barrier (BBB) to a site of TDP-43 protein aggregation, wherein the anti-TDP-43 Fab comprises;
- a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH comprises heavy chain complementarity-determining regions (CDRs) comprising a CDR1 having the amino acid sequence of SEQ ID NO:
- 19;
- a CDR2 having the amino acid sequence of SEQ ID NO:
- 20;
- and a CDR3 having the amino acid sequence of SEQ ID NO:
- 21;
- and the VL comprises light chain CDRs comprising a CDR1 having the amino acid sequence of SEQ ID NO:
- 22;
- a CDR2 having the amino acid sequence of SEQ ID NO:
- 23;
- and a CDR3 having the amino acid sequence of SEQ ID NO:
- 24.
Dependencies are inferred from the claim text.